In conclusion, we have identified an FDA-approved ATG4B inhibitor based on its high potency in ATG4B inhibition both in vitro and in vivo, and generating desirable suppression of autophagy and proliferation of xenografted CRC cell tumors. This evidence concerns the gene ATG4B and colorectal carcinoma.